title: Modeling the impact of prevention policies on future diabetes prevalence in the United States: 2010-2030.
abstract: BACKGROUND
  Although diabetes is one of the most costly and rapidly increasing serious chronic diseases worldwide, the optimal mix of strategies to reduce diabetes prevalence has not been determined.
  
  
  METHODS
  Using a dynamic model that incorporates national data on diabetes prevalence and incidence, migration, mortality rates, and intervention effectiveness, we project the effect of five hypothetical prevention policies on future US diabetes rates through 2030: 1) no diabetes prevention strategy; 2) a "high-risk" strategy, wherein adults with both impaired fasting glucose (IFG) (fasting plasma glucose of 100-124 mg/dl) and impaired glucose tolerance (IGT) (2-hour post-load glucose of 141-199 mg/dl) receive structured lifestyle intervention; 3) a "moderate-risk" strategy, wherein only adults with IFG are offered structured lifestyle intervention; 4) a "population-wide" strategy, in which the entire population is exposed to broad risk reduction policies; and 5) a "combined" strategy, involving both the moderate-risk and population-wide strategies. We assumed that the moderate- and high-risk strategies reduce the annual diabetes incidence rate in the targeted subpopulations by 12.5% through 2030 and that the population-wide approach would reduce the projected annual diabetes incidence rate by 2% in the entire US population.
  
  
  RESULTS
  We project that by the year 2030, the combined strategy would prevent 4.6 million incident cases and 3.6 million prevalent cases, attenuating the increase in diabetes prevalence by 14%. The moderate-risk approach is projected to prevent 4.0 million incident cases, 3.1 million prevalent cases, attenuating the increase in prevalence by 12%. The high-risk and population approaches attenuate the projected prevalence increases by 5% and 3%, respectively. Even if the most effective strategy is implemented (the combined strategy), our projections indicate that the diabetes prevalence rate would increase by about 65% over the 23 years (i.e., from 12.9% in 2010 to 21.3% in 2030).
  
  
  CONCLUSIONS
  While implementation of appropriate diabetes prevention strategies may slow the rate of increase of the prevalence of diabetes among US adults through 2030, the US diabetes prevalence rate is likely to increase dramatically over the next 20 years. Demand for health care services for people with diabetes complications and diabetes-related disability will continue to grow, and these services will need to be strengthened along with primary diabetes prevention efforts.
authors.affiliation: Division of Diabetes Translation, National Center for Chronic Disease Prevention and Health Promotion, Centers for Disease Control and Prevention, Atlanta, GA 30341, USA. edg7@cdc.gov.
authors.forename: Edward W
authors.initials: EW
authors.lastname: Gregg
authors.forename: James P
authors.initials: JP
authors.lastname: Boyle
authors.forename: Theodore J
authors.initials: TJ
authors.lastname: Thompson
authors.forename: Lawrence E
authors.initials: LE
authors.lastname: Barker
authors.forename: Ann L
authors.initials: AL
authors.lastname: Albright
authors.forename: David F
authors.initials: DF
authors.lastname: Williamson
references.citation: Br Med J (Clin Res Ed). 1983 Jun 11;286(6381):1857-60
references.pmid: 6407602
references.citation: Diabetes Care. 1997 Jul;20(7):1101-7
references.pmid: 9203444
references.citation: JAMA. 1989 Jan 6;261(1):61-5
references.pmid: 2908996
references.citation: Evid Rep Technol Assess (Summ). 2005 Aug;(128):1-11
references.pmid: 16194123
references.citation: Am J Epidemiol. 2010 Sep 1;172(5):501-16
references.pmid: 20667932
references.citation: Diabetes Care. 2008 Feb;31(2):267-72
references.pmid: 17989310
references.citation: Diabetes Care. 2006 Sep;29(9):2114-6
references.pmid: 16936162
references.citation: Am J Prev Med. 2006 May;30(5):371-7
references.pmid: 16627124
references.citation: BMJ. 2006 Mar 18;332(7542):659-62
references.pmid: 16543339
references.citation: N Engl J Med. 2001 May 3;344(18):1343-50
references.pmid: 11333990
references.citation: Diabetes Care. 2010 Jan;33 Suppl 1:S62-9
references.pmid: 20042775
references.citation: Lancet. 2000 Aug 26;356(9231):757-61
references.pmid: 11085708
references.citation: Diabetes Res Clin Pract. 2009 Dec;86(3):225-32
references.pmid: 19833403
references.citation: Am J Prev Med. 2010 Feb;38(2 Suppl):S237-62
references.pmid: 20117610
references.citation: Lancet. 2011 Jul 2;378(9785):31-40
references.pmid: 21705069
references.citation: Diabetologia. 1997 Jan;40(1):62-6
references.pmid: 9028719
references.citation: Int J Epidemiol. 2001 Jun;30(3):427-32; discussion 433-4
references.pmid: 11416056
references.citation: Diabetologia. 2011 Feb;54(2):300-7
references.pmid: 21046360
references.citation: N Engl J Med. 2011 Mar 03;364(9):829-841
references.pmid: 21366474
references.citation: N Engl J Med. 1993 Jun 10;328(23):1676-85
references.pmid: 8487827
references.citation: Psychol Bull. 2007 Mar;133(2):205-26
references.pmid: 17338597
references.citation: Diabetes Care. 2009 Nov;32(11):2133-5
references.pmid: 19875608
references.citation: Diabetes Care. 2011 Jul;34(7):1451-7
references.pmid: 21593290
references.citation: Nat Clin Pract Endocrinol Metab. 2008 Jul;4(7):382-93
references.pmid: 18493227
references.citation: N Engl J Med. 2007 Feb 1;356(5):437-40
references.pmid: 17267901
references.citation: Diabetologia. 2006 Feb;49(2):289-97
references.pmid: 16391903
references.citation: Popul Health Metr. 2010 Oct 22;8:29
references.pmid: 20969750
references.citation: J Hum Hypertens. 2007 Feb;21(2):99-106
references.pmid: 17136106
references.citation: Diabetes Res Clin Pract. 2011 Dec;94(3):311-21
references.pmid: 22079683
references.citation: Diabetes Care. 2011 Jun;34(6):1424-30
references.pmid: 21602431
references.citation: Am J Prev Med. 2008 Oct;35(4):357-63
references.pmid: 18779029
references.citation: BMJ. 2007 Feb 10;334(7588):299
references.pmid: 17237299
references.citation: Circulation. 2009 Apr 7;119(13):1728-35
references.pmid: 19307472
references.citation: N Engl J Med. 2009 Oct 15;361(16):1599-605
references.pmid: 19759377
references.citation: Diabetes Care. 2009 Dec;32(12):2225-9
references.pmid: 19940225
references.citation: JAMA. 2009 Apr 15;301(15):1596-8
references.pmid: 19366782
references.citation: N Engl J Med. 2002 Feb 7;346(6):393-403
references.pmid: 11832527
references.citation: Diabetes. 1991 Jul;40(7):796-9
references.pmid: 2060716
references.citation: Diabetes Care. 2001 Mar;24(3):447-53
references.pmid: 11289466
references.citation: Lancet. 2008 May 24;371(9626):1783-9
references.pmid: 18502303
references.citation: N Engl J Med. 2008 Feb 7;358(6):580-91
references.pmid: 18256393
references.citation: Ann Intern Med. 2007 Aug 7;147(3):149-55
references.pmid: 17576993